Chamberlain University
NR 546 / NR546
Week 3
Antipsychotics Table
Course: Advanced Pharmacology
, lOMoARcPSD|51648332
Drug name Indication Half-life (T1/2), Notable side effects (associate to pathway or
Target symptoms: state if positive or negative effect metabolism (CYP 450 NT)
Potency (if noted. receptor occupancy if noted ) enzyme)
Neurotransmitter(s) affected
Typical antipsychotics (conventional)
Haloperidol Target symptoms: Half-Life: Haldol Neuroleptic-induced deficit syndrome
Manifestations of psychotic disorders Tics and vocal decanoate: Akathisia
utterances in Tourette’s Syndrome Second-line approximately 3 Drug-induced parkinsonism
treatment of severe behavior problems in children weeks Oral: 12-38 Tardive dyskinesia, dystonia
of combative, explosive, hyperexcitability Second- hours Irreversible involuntary dyskinetic movements
line short-term treatment of hyperactive children Galactorrhea, amenorrhea Dizziness,
Treatment of schizophrenic patients who require Metabolism: sedation
prolonged parenteral antipsychotic therapy Bipolar CYP1A2, CYP2D6, Dry mouth
Disorder Behavioral disturbances in dementias CYP3A4 Constipation
Delirium (with lorazepam) Positive symptoms of Urinary retention
psychosis, violent or aggressive behavior Blurred vision
Potency: High potency first-generation Decreased sweating
Neurotransmitter(s) affected: Hypotension
Blocks dopamine 2 receptors, reducing positive Tachycardia
symptoms of psychosis and combative, explosive, Hypertension
and hyperactive behaviors Blocks dopamine 2 Weight gain
receptors in the nigrostriatal pathway, improving
tics and other symptoms in Tourette’s syndrome
Thioridazine Target symptoms: Used for Schizophrenia in Half-Life: 21-24 Neuroleptic-induced deficit syndrome
patients who fail to respond to treatment with hours Akathisia
other antipsychotic drugs Positive symptoms of Priapism
psychosis Metabolism: Drug-induced parkinsonism
Motor and autonomic hyperactivity Violent or CYP450 2D6 Tardive dyskinesia
aggressive behavior Irreversible involuntary dyskinetic movements
Potency: Low-potency first-generation Galactorrhea, amenorrhea
Neurotransmitter(s) affected: Blocks dopamine 2 Pigmentary retinopathy
receptors, reducing positive symptoms of psychosis Dizziness, sedation
NR 546 / NR546
Week 3
Antipsychotics Table
Course: Advanced Pharmacology
, lOMoARcPSD|51648332
Drug name Indication Half-life (T1/2), Notable side effects (associate to pathway or
Target symptoms: state if positive or negative effect metabolism (CYP 450 NT)
Potency (if noted. receptor occupancy if noted ) enzyme)
Neurotransmitter(s) affected
Typical antipsychotics (conventional)
Haloperidol Target symptoms: Half-Life: Haldol Neuroleptic-induced deficit syndrome
Manifestations of psychotic disorders Tics and vocal decanoate: Akathisia
utterances in Tourette’s Syndrome Second-line approximately 3 Drug-induced parkinsonism
treatment of severe behavior problems in children weeks Oral: 12-38 Tardive dyskinesia, dystonia
of combative, explosive, hyperexcitability Second- hours Irreversible involuntary dyskinetic movements
line short-term treatment of hyperactive children Galactorrhea, amenorrhea Dizziness,
Treatment of schizophrenic patients who require Metabolism: sedation
prolonged parenteral antipsychotic therapy Bipolar CYP1A2, CYP2D6, Dry mouth
Disorder Behavioral disturbances in dementias CYP3A4 Constipation
Delirium (with lorazepam) Positive symptoms of Urinary retention
psychosis, violent or aggressive behavior Blurred vision
Potency: High potency first-generation Decreased sweating
Neurotransmitter(s) affected: Hypotension
Blocks dopamine 2 receptors, reducing positive Tachycardia
symptoms of psychosis and combative, explosive, Hypertension
and hyperactive behaviors Blocks dopamine 2 Weight gain
receptors in the nigrostriatal pathway, improving
tics and other symptoms in Tourette’s syndrome
Thioridazine Target symptoms: Used for Schizophrenia in Half-Life: 21-24 Neuroleptic-induced deficit syndrome
patients who fail to respond to treatment with hours Akathisia
other antipsychotic drugs Positive symptoms of Priapism
psychosis Metabolism: Drug-induced parkinsonism
Motor and autonomic hyperactivity Violent or CYP450 2D6 Tardive dyskinesia
aggressive behavior Irreversible involuntary dyskinetic movements
Potency: Low-potency first-generation Galactorrhea, amenorrhea
Neurotransmitter(s) affected: Blocks dopamine 2 Pigmentary retinopathy
receptors, reducing positive symptoms of psychosis Dizziness, sedation
